ERBB2 and breast carcinoma: For patients who have failed TKI treatment, we should adhere to the concept of “continuous anti HER2 treatment” and continue to suppress HER2 driver genes.8,9 The Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guideline 2023 recommends HP+C as subsequent regimens after TKI failure for patients who have not been administered pertuzumab before.